SYnAbs

SYnAbs is a private, pre-clinical stage biotech firm developing therapeutic antibodies for autoimmune and inflammatory disorders. Operating from Liège, Belgium, the company is likely pre-revenue, relying on funding to advance its pipeline. Its core value proposition lies in its proprietary antibody discovery platform, which aims to generate differentiated candidates against validated and novel targets in high-need therapeutic areas.

Proprietary antibody discovery and engineering platform for generating therapeutic antibodies against autoimmune and inflammatory disease targets.

SYnAbs operates in a highly competitive landscape dominated by major pharmaceutical companies (e.g., AbbVie, Johnson & Johnson, Novartis, Roche) with multiple approved blockbuster antibodies. It also competes with dozens of clinical-stage biotechs pursuing novel targets and improved antibody formats. Differentiation requires truly novel mechanisms or superior product profiles.